TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...

Daiichi Sankyo's stock has dropped 25% since my last update due to disappointing clinical data from Dato-DXd studies, but upcoming read-outs in 2025 could drive a meaningful rebound. Dato-DXd ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...

Daiichi Sankyo (OTCPK:DSKYF) stock slid 10% Friday after the Japanese drugmaker announced it had received approval in Japan for its DXd antibody-drug conjugate Datroway for the treatment of HR+ ...

German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid ...

AstraZeneca, a global, science-led biopharmaceutical company, and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with ...

Kartik Aaryan was recently honoured with a degree at the convocation ceremony of DY Patil University in Mumbai, over a decade after he initially enrolled in the course. The actor took to Instagram ...

Kartik Aaryan was seen in a new look inspired by Allu Arjun's character Pushpa Raj from 'Pushpa 2: The Rule'. This appearance coincides with his latest project 'Tu Meri Main Tera', marking a ...

A paparazzo handle on Instagram shared a video from Kartik's outing in Mumbai from Wednesday evening. Kartik wore a light grey T-shirt with matching denims and cap. He teased the paparazzi while ...

(Bloomberg) -- AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European Union in a blow for the experimental drug. The two ...